Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA

Watchlist Manager
Kiniksa Pharmaceuticals Ltd Logo
Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA
Watchlist
Price: 28.3 USD 2.06% Market Closed
Market Cap: 2.1B USD

Wall Street
Price Targets

KNSA Price Targets Summary
Kiniksa Pharmaceuticals Ltd

Wall Street analysts forecast KNSA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for KNSA is 36.92 USD with a low forecast of 30.3 USD and a high forecast of 47.25 USD.

Lowest
Price Target
30.3 USD
7% Upside
Average
Price Target
36.92 USD
30% Upside
Highest
Price Target
47.25 USD
67% Upside
Kiniksa Pharmaceuticals Ltd Competitors:
Price Targets
CVAC
CureVac NV
24% Upside
GMAB
Genmab A/S
39% Upside
IVA
Inventiva SA
208% Upside
1952
Everest Medicines Ltd
8% Upside
AMGN
Amgen Inc
8% Upside
301207
Hualan Biological Bacterin Inc
19% Upside
LXRX
Lexicon Pharmaceuticals Inc
292% Upside
688278
Xiamen Amoytop Biotech Co Ltd
39% Upside

Revenue
Forecast

Revenue Estimate
Kiniksa Pharmaceuticals Ltd

The compound annual growth rate of Kiniksa Pharmaceuticals Ltd's revenue for the next 3 years is 26%.

N/A
Past Growth
26%
Estimated Growth
Estimates Accuracy
2%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Kiniksa Pharmaceuticals Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
3%
Average Beat

Net Income
Forecast

Net Income Estimate
Kiniksa Pharmaceuticals Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-8%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is KNSA's stock price target?
Price Target
36.92 USD

According to Wall Street analysts, the average 1-year price target for KNSA is 36.92 USD with a low forecast of 30.3 USD and a high forecast of 47.25 USD.

What is Kiniksa Pharmaceuticals Ltd's Revenue forecast?
Projected CAGR
26%

The compound annual growth rate of Kiniksa Pharmaceuticals Ltd's revenue for the next 3 years is 26%.

Back to Top